Medical Ikkou Group Co.,Ltd. (TYO:3353)
2,691.00
+1.00 (0.04%)
Jun 16, 2026, 3:30 PM JST
Medical Ikkou Group Income Statement
Financials in millions JPY. Fiscal year is March - February.
Millions JPY. Fiscal year is Mar - Feb.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
| 54,982 | 48,393 | 39,900 | 33,897 | 33,595 | |
Revenue Growth (YoY) | 13.62% | 21.29% | 17.71% | 0.90% | 6.30% |
Cost of Revenue | 48,497 | 42,649 | 35,349 | 30,715 | 29,982 |
Gross Profit | 6,485 | 5,744 | 4,551 | 3,182 | 3,613 |
Selling, General & Admin | 4,263 | 3,620 | 2,544 | 1,713 | 1,765 |
Amortization of Goodwill & Intangibles | 121 | 138 | 171 | 209 | 242 |
Other Operating Expenses | 308 | 290 | 277 | 325 | 331 |
Operating Expenses | 4,697 | 4,052 | 2,992 | 2,247 | 2,338 |
Operating Income | 1,788 | 1,692 | 1,559 | 935 | 1,275 |
Interest Expense | -102 | -63 | -54 | -50 | -58 |
Interest & Investment Income | 100 | 72 | 47 | 39 | 30 |
Other Non Operating Income (Expenses) | 173 | 114 | 198 | 301 | 110 |
EBT Excluding Unusual Items | 1,959 | 1,815 | 1,750 | 1,225 | 1,357 |
Gain (Loss) on Sale of Investments | 169 | 117 | 167 | 36 | 106 |
Gain (Loss) on Sale of Assets | 4 | 77 | -2 | 20 | 28 |
Asset Writedown | -65 | -208 | -256 | -36 | -10 |
Other Unusual Items | -43 | 99 | 2 | 67 | -5 |
Pretax Income | 2,024 | 1,900 | 1,661 | 1,312 | 1,476 |
Income Tax Expense | 710 | 754 | 581 | 540 | 607 |
Earnings From Continuing Operations | 1,314 | 1,146 | 1,080 | 772 | 869 |
Minority Interest in Earnings | -39 | -13 | -41 | -13 | -17 |
Net Income | 1,275 | 1,133 | 1,039 | 759 | 852 |
Net Income to Common | 1,275 | 1,133 | 1,039 | 759 | 852 |
Net Income Growth | 12.53% | 9.05% | 36.89% | -10.91% | 1.91% |
Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 |
Shares Change (YoY) | 0.10% | 0.07% | 0.03% | 0.02% | -0.45% |
EPS (Basic) | 338.72 | 301.31 | 276.50 | 202.04 | 226.83 |
EPS (Diluted) | 338.72 | 301.31 | 276.50 | 202.04 | 226.83 |
EPS Growth | 12.41% | 8.97% | 36.85% | -10.93% | 2.37% |
Free Cash Flow | 682 | 202 | 3,975 | 996 | 813 |
Free Cash Flow Per Share | 181.18 | 53.72 | 1057.83 | 265.13 | 216.45 |
Dividend Per Share | 120.000 | 60.000 | 45.000 | 40.000 | 40.000 |
Dividend Growth | 100.00% | 33.33% | 12.50% | - | -50.00% |
Gross Margin | 11.79% | 11.87% | 11.41% | 9.39% | 10.76% |
Operating Margin | 3.25% | 3.50% | 3.91% | 2.76% | 3.79% |
Profit Margin | 2.32% | 2.34% | 2.60% | 2.24% | 2.54% |
Free Cash Flow Margin | 1.24% | 0.42% | 9.96% | 2.94% | 2.42% |
EBITDA | 2,631 | 2,454 | 2,342 | 1,776 | 2,145 |
EBITDA Margin | 4.78% | 5.07% | 5.87% | 5.24% | 6.39% |
D&A For EBITDA | 843 | 762 | 783 | 841 | 870 |
EBIT | 1,788 | 1,692 | 1,559 | 935 | 1,275 |
EBIT Margin | 3.25% | 3.50% | 3.91% | 2.76% | 3.79% |
Effective Tax Rate | 35.08% | 39.68% | 34.98% | 41.16% | 41.13% |